People with HIV who were hospitalized with COVID-19 didn’t have worse results than COVID-19 patients without HIV, new research shows.
“Throughout the pandemic, we’ve suspected that immunocompromised patients, such as those with HIV, could be at a higher risk for infection and suffer more severe outcomes, but without data on how COVID-19 affects patients with HIV specifically, clinical guidance for managing and advising these patients has been lacking,” said study author Dr. Keith Sigel.
He’s a member of the Mount Sinai COVID Informatics Center at the Icahn School of Medicine at Mount Sinai, in New York City.
People with a weakened immune system often have worse outcomes when they develop serious infections. HIV is one of the most common causes of immunodeficiency in the world and affects more than one million people in the United States.
For the study, researchers compared COVID-19 patients with and without HIV at five hospitals in the Mount Sinai Health System in New York City. The patients were assessed at the peak of the pandemic in the city during March and April.
Death rates and poor outcomes – such as respiratory failure or multiorgan dysfunction – were high among patients with HIV, but no worse than among those without HIV, the researchers found.
The patients with HIV did not have evidence of significant immune suppression or elevated HIV viral levels, according to the study published June 28 in the journal Clinical Infectious Diseases.
This study adds to existing limited evidence that HIV may not be associated with more severe COVID-19 symptoms, the researchers said.
“This study sets the foundation for future studies in larger cohorts so we can appropriately address treating COVID-19 in patients with HIV,” Sigel said in a Mount Sinai news release.
This retrospective analysis included all cases of PLWH with SARS-CoV-2 infection, which were confirmed between March 11 and April 17, 2020 in 12 participating German HIV centers.
Anonymized data were collected by the treating physicians and included age, gender and HIV-associated parameters such as the last CD4+ T cells (absolute cells/mm3, as assessed by local labs), the last CD4/CD8 ratio, the last HIV-RNA (copies/mL, as assessed by local labs) and antiretroviral therapy before COVID-19 diagnosis.
With regard to COVID-19, clinical symptoms, severity of disease classified as mild (i.e., non-pneumonia and mild pneumonia), severe (i.e., dyspnea, respiratory frequency ≥ 30/min, blood oxygen saturation ≤ 93%, and/or lung infiltrates > 50% within 24–48 h), and critical (i.e., respiratory failure, septic shock, and/or multiple organ dysfunction or failure) [10], and outcome were collected as well as comorbidities. Ethics committee approval was obtained from Technical University of Munich (April 4, 2020, Approval No. 194/20s).
Results
We identified 33 PLWH with confirmed SARS-CoV-2 infection. Positive SARS-CoV-2 PCR was obtained from nasopharyngeal swabs in 29, and from bronchoalveolar lavage or sputum in 2 cases; in two cases, no information about this was available.
For 14 patients, a close contact to a person with SARS-CoV-2 infection has been documented. For seven patients, a travel history to foreign countries with a high transmission rate of SARS-CoV-2 has been reported. 26 patients were primarily diagnosed in the outpatient setting.
In 7 patients, the diagnostic procedure was done in the hospitals during admission. Additionally, neither clusters of transmission nor nosocomial infections could be detected. Main characteristics are shown in Table Table1.1.
Mean age was 48 years (range 26–82 years) and 30/33 patients were men. All patients were on antiretroviral therapy at the time of COVID-19 diagnosis. Antiretroviral regimens included nucleoside reverse transcriptase inhibitors (NRTIs) in 31, integrase strand transfer inhibitors (INSTI) in 20, protease inhibitors (PI) in 4 and Non-NRTIs in 9 cases. NRTIs were mainly tenofovir alafenamide (16 cases), tenofovir disoproxilfumarate (6 cases) and a cytidine analog, either emtricitabine (n = 22) or lamivudine (n = 9).
The last median CD4+ T-cell count before SARS-CoV-2 infection was 670/mm3 (range 69–1715/mm3). In 30/32 cases, the last HIV-RNA was below 50 copies/mL. Two patients with detectable HI-viremia needed hospital admission including intensive care treatment and mechanical ventilation, and one of these patients died.
Comorbidities other than HIV infection were documented in 20/33 (60%) patients, including arterial hypertension (n = 10), chronic obstructive pulmonary disease (n = 6), diabetes mellitus (n = 4), cardiovascular disease (n = 3) and renal insufficiency (n = 2).
Coinfection with hepatitis B has been documented in five patients: a resolved hepatitis B (hepatitis B surface antigen negative) in four patients, and in one patient a chronic hepatitis B (hepatitis B envelope antigen positive). In one patient, a cured hepatitis C (sustained virologic response after 12 weeks of treatment with sofosbuvir/velpatasvir) has been reported.
Table 1
Patient characteristics
| Age (years) | Sex | Years since HIV diagnosis | Antiretroviral treatment (ART) | Years of ART | CD4 T-cell count per mm3 | CD4/CD8 ratio | CD4 T-cell nadir (count per mm3) | HIV-RNA (copies/mL) | COVID-19 clinical classification | Outcome | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 44 | M | 14 | DTG/ABC/3TC | 13 | 754 | 0.83 | 163 | < 50 | Mild | Recovered |
| 2 | 33 | F | 7 | RPV/TAF/FTC | 6 | 619 | 0.9 | 387 | < 50 | Mild | Recovered |
| 3 | 38 | M | 3 | BIC/TAF/FTC | 2 | 1187 | 1.52 | 541 | < 50 | Mild | Recovered |
| 4 | 53 | M | 11 | NVP/ABC/3TC | 11 | 810 | 0.53 | 293 | < 50 | Mild | Recovered |
| 5 | 60 | M | 7 | DTG/TDF/FTC | 5.5 | 892 | 1.00 | 362 | < 50 | Mild | Recovered |
| 6 | 51 | M | 20 | DTG/3TC | 10 | 402 | 0.4 | 329 | < 50 | Mild | Recovered |
| 7 | 42 | M | 17 | DTG/ABC/3TC | 5.5 | 1087 | 0.9 | 439 | < 50 | Mild | Recovered |
| 8 | 65 | M | 13 | BIC/TAF/FTC | 9 | 1122 | 0.93 | 490 | < 50 | Mild | Recovered |
| 9 | 82 | M | 28 | DRV/RTV/RGV | 28 | 379 | 0.4 | 151 | 920 | Critical | ICU, NIV, death |
| 10 | 53 | M | 10 | DRV/COBI/TAF/FTC | 0.5 | 285 | 0.25 | 204 | 842 | Critical | ICU, IV, discharged, recovered |
| 11 | 32 | M | 10 | DRV/COBI/TAF/FTC | 10 | 731 | 1.89 | 325 | < 50 | Mild | Recovered |
| 12 | 31 | M | 5 | EVG/COBI/TAF/FTC | 5 | 1000 | 1.15 | 810 | < 50 | Mild | Recovered |
| 13 | 37 | M | 10 | EVG/COBI/TAF/FTC | 8 | 946 | 1.13 | 580 | < 50 | Mild | Recovered |
| 14 | 37 | F | 5 | DOR/TDF/FTC | 5 | 402 | 0.5 | na | < 50 | Severe | Hospital, discharged, recovered |
| 15 | 36 | M | 4 | DTG/ABC/3TC | 4 | 718 | 1.2 | na | < 50 | Critical | ICU, IV, discharged from ICU, Hospital |
| 16 | 68 | M | 14 | DRV/COBI/TAF/FTC | 14 | 499 | 0.9 | 240 | < 50 | Severe | Hospital, discharged, recovered |
| 17 | 42 | M | 11 | RPV/TDF/FTC | na | 613 | 1.3 | 430 | < 50 | Critical | ICU, discharged, recovered |
| 18 | 35 | M | 3 | DTG/3TC | na | 538 | 1.0 | 419 | < 50 | Mild | Recovered |
| 19 | 55 | M | 10 | RPV/TAF/FTC | 10 | 780 | 1.89 | 370 | < 50 | Mild | Recovered |
| 20 | 55 | M | 21 | BIC/TAF/FTC | 21 | 69 | 0.06 | 8 | < 50 | Critical | ICU, IV, death |
| 21 | 58 | M | 16 | DTG | 14 | 573 | 0.8 | 314 | < 50 | Mild | Recovered |
| 22 | 30 | M | 6 | DTG/ABC/3TC | 6 | 608 | 1.00 | 608 | < 50 | Mild | Recovered |
| 23 | 26 | M | na | BIC/TAF/FTC | na | na | na | na | na | Mild | Recovered |
| 24 | 59 | M | 15 | DOR/TDF/FTC | 15 | 718 | 1.75 | 230 | < 50 | Critical | ICU, IV, death |
| 25 | 31 | M | 7 | BIC/TAF/FTC | 5 | 647 | 1.09 | 390 | < 50 | Mild | Recovered |
| 26 | 62 | M | 20 | NVP/TAF/FTC | 20 | 692 | 4.94 | 111 | < 50 | Mild | Recovered |
| 27 | 53 | M | 6 | EVG/COBI/TAF/FTC | 6 | 717 | 0.95 | 457 | < 50 | Mild | Recovered |
| 28 | 54 | M | 15 | BIC/TAF/FTC | 15 | 437 | 0.68 | 126 | < 50 | Mild | Hospital, discharged, recovered |
| 29 | 70 | M | 13 | NVP/TAF/FTC | 13 | 336 | 0.38 | 250 | < 50 | Mild | Hospital, discharged, recovered |
| 30 | 48 | M | 11 | DTG/3TC | 3 | 1715 | 0.91 | 474 | < 50 | Mild | Hospital, discharged, recovered |
| 31 | 35 | M | 1 | RPV/TAF/FTC | 1 | 490 | 0.55 | na | < 50 | Mild | Hospital, discharged, recovered |
| 32 | 45 | F | 5 | DTG/TDF/FTC | 5 | 234 | 0.34 | 150 | < 50 | Mild | Hospital, discharged, recovered |
| 33 | 66 | M | 31 | DTG/ABC/3TC | na | 1250 | 1.76 | na | < 50 | Mild |
The most common symptoms were cough in 25/32 (78%), fever in 22/32 (69%), arthralgia/myalgia 7/32 (22%), headache 7/32 (22%), and sore throat in 7/32 (22%). Sinusitis and anosmia occurred in 6/32 (19%) for each.
At the last available follow-up, 29/32 of patients with documented outcome (91%) had recovered from COVID-19. Altogether, 14/33 (42%) patients were admitted to hospitals. Treatment on intensive care units (ICU) was necessary in 6 of 14 (43%) hospitalized patients.
Of the 14 patients, requiring treatment in hospitals, 10 have been discharged in the meanwhile. One patient is still in hospital but discharged from ICU. In one patient, a spontaneous pneumothorax could be seen as a complication of persisting cough.
Three out of 32 patients with documented outcome (9%) had died (patient #9 aged 82 years, patient #20 with a CD4+ T-cell count of 69/mm3 and a very low CD4/CD8 ratio of 0.06, and patient #24 with several comorbidities as hypertension, chronic obstructive pulmonary disease, and diabetes mellitus type 2). The clinical case definition was mild in 25/33 cases (76%), severe in 2/33 cases (6%), and critical in 6/33 cases (18%).
Discussion
In the current COVID-19 pandemic, comorbidities such as arterial hypertension, cardiovascular disease, diabetes and cancer have been identified as risk factors for severe diseases [2–5].
However, as these cohort studies did not provide data on HIV infection, it remains unclear whether PLWH remain at higher risk for SARS-CoV-2 infection or at higher risk for severe courses. Previous studies on influenza viruses did not find an increased morbidity and mortality in PLWH [11, 12].
For SARS and COVID-19, a few case reports have indicated no severe courses even in AIDS patients [13, 14]. In the absence of controlled and/or larger data, a preliminary statement from the European AIDS Clinical Society explained that “there is no evidence for a higher COVID-19 infection rate or different disease course in people with HIV than in HIV-negative people” so far [15].
In the present case series on 33 patients infected with symptomatic SARS-CoV-2 infection, 29/32 (91%) have recovered at the last follow-up and 76% have been classified as mild cases. However, 24% of the cases have been categorized as severe or critical cases.
Three patients had died (9%). The following details provide some explanations: One patient was of older age (82 years) and had a detectable viral load before COVID-19. In the other deceased patient, only limited information was available but his last CD4 T-cell count and CD4/CD8 ratio were very low.
The third patient suffered from several comorbidities as arterial hypertension, chronic pulmonary obstructive disease, and diabetes mellitus type 2. The case fatality rate of 9% is, therefore, higher than in the general population in Germany, where about 5640 patients of 154,175 confirmed COVID-19 cases died (3.7%) [16].
Additionally, the number of severe and critical cases in our cohort (24%) seems to be somewhat higher than that reported from other cohorts (19%) [10]. The hospitalization rate in our cohort was 42% and, therefore, higher than in the general population in Germany, where the hospitalization rate of COVID-19 patients is about 17% [16].
Of the 14 hospitalized patients, 6/14 (43%) needed an admission to an intensive care unit. On the first look, this seems to be higher than it was reported in a large cohort in New York, where the ICU admission rate of patients with documented outcome was 14% [17].
This could be due to involvement of two large university hospitals where only hospitalized patients were included. In addition, there might be an effect of higher hospitalization rates among patients with known HIV infection due to safety reasons.
Nevertheless, the precise hospitalization rate among symptomatic cases is not known. In our cohort, only symptomatic patients were documented. In larger cohorts, it has been estimated that about 20–40% of SARS-CoV-2 infected people are asymptomatic [18, 19].
Therefore, it is very likely that we have overestimated total morbidity and mortality. Another aspect is the different mean age in large cohorts (63 years) [17] and in our cohort.
The mean age of 48 years in our cohort may correspond not only to the younger HIV infected population but also to the lower mean age of SARS-CoV-2 infected people in Germany of 50 years [16]. The main symptoms reported in our cohort were mainly cough and fever. The clinical characteristics of COVID-19 did not appear to differ from those of the general population [2, 5, 16].
All patients were on ART and all except four had CD4+ T-cells > 350/mm3, indicating no severe immune deficiency. However, two patients with a detectable viremia required mechanical ventilation.
Nevertheless, the data obtained did not reflect whether this was due to an insufficient antiretroviral treatment regimen, a treatment failure, or maybe due to the present COVID-19 disease.
There are some data on immunological consequences from two retrospective studies of 21 and 44 HIV-negative patients with COVID-19, showing significant decreases of CD4+ T-cells in almost all patients, with a more pronounced decline in severe cases [8, 9].
There is also evidence from a larger study on SARS-CoV, showing a prolonged lymphopenia before returning towards normal after 5 weeks, with the lowest mean CD4+ T-cell count of 317 cells/µl [7]. Up to now, it remains unclear whether this may translate into a higher risk for opportunistic infections.
We have identified 4/33 patients who acquired SARS-CoV-2, while these patients were treated with a PI containing regimen, consisting in boosted darunavir in all cases. This percentage does not appear to differ markedly from the total PLWH population in Germany, in which the proportion of patients on boosted PIs has constantly decreased during recent years [20, 21].
For another HIV-PI, lopinavir, uncontrolled studies have indicated a potential benefit in COVID-19 with early initiation [22–24]. In addition, a case–control study on Middle East Respiratory Syndrome (MERS) has suggested an effect for lopinavir/ritonavir as post-exposure prophylaxis in health care workers [25].
However, the first randomized open-label trial in 199 adults with severe COVID-19 did not find any clinical or virological benefit with lopinavir/ritonavir beyond standard care [26]. It was speculated that concentrations of protein-unbound lopinavir achieved by current HIV dosing are too low for inhibiting viral replication.
Nevertheless, several trials of lopinavir and darunavir are ongoing, including a cluster-randomized clinical trial on 3.040 participants in Spain (HCQ4COV19). Our preliminary findings did not suggest a protective effect of darunavir which is in line with US Guidelines, recommending that ART regimen “should not be changed to include a PI to prevent or treat COVID-19, except in the context of a clinical trial and in consultation with an HIV specialist” [27].
Besides PI, we did not find a clear evidence for a protective effect of tenofovir. Of note, the nucleoside analog remdesivir, which is currently tested in several clinical trials for COVID-19 [28], has some chemical similarities to tenofovir alafenamide.
In molecular docking studies, tenofovir has been recently shown to bind to SARS-CoV-2 RNA polymerase (RdRp) with binding energies comparable to those of native nucleotides und to a similar extent as remdesivir. Consequently, tenofovir has recently been suggested as a potential treatment for COVID-19 [29].
In Spain, a large randomized phase 3 placebo-controlled study compares the use of tenofovir disoproxil fumarate/emtricitabine, hydroxychloroquine or the combination of both versus placebo as prophylaxis for COVID-19 in healthcare works [30].
As the majority of our patients (22/33) was treated with tenofovir alafenamide or tenofovir disoproxil fumarate, including those developing severe or critical disease, our cohort data indicate no or only minimal clinical effect of tenofovir against SARS-CoV-2.
There is no doubt that our study has important limitations. First, this was a small retrospective and uncontrolled case series with limited follow-up. All patients were symptomatic, indicating that asymptomatic cases were probably missed.
For the antiretroviral treatment regimen, we did not have the precise rates of overall PI or tenofovir prescriptions in the participating centers. Other important data were incomplete, including transmission and exposure conditions. In addition, detailed information about the onset, duration, intensity of the symptoms, and radiological details of CT scans were limited or not obtained in our retrospective analysis.
In conclusion, this preliminary case series does not support an excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART. Larger studies are needed to elucidate any protective or deleterious effect of HIV and antiretroviral therapy.
References
1. World Health Organization (WHO) (2019) Coronavirus disease (COVID-19) outbreak situation. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. [PubMed] [CrossRef] [Google Scholar]
3. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337. doi: 10.1016/S1470-2045(20)30096-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24:108. doi: 10.1186/s13054-020-2833-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, Miro JM. COVID-19 in HIV investigators. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020 doi: 10.1016/S2352-3018(20)30111-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. He ZC, Dong Q, Zhuang H, Song S, Peng G, Dwyer DE. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9:323–330. doi: 10.1016/j.ijid.2004.07.014. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020;2020:137244. [Google Scholar]
9. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa248. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
10. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
11. Peters PJ, Skarbinski J, Louie JK, et al. HIV-infected hospitalized patients with 2009 pandemic influenza A (pH1N1)—United States, spring and summer 2009. Clin Infect Dis. 2011;52(1):S183–S188. doi: 10.1093/cid/ciq036. [PubMed] [CrossRef] [Google Scholar]
12. Lynfield R, Davey R, Dwyer DE, et al. Outcomes of influenza A (H1N1) pdm09 virus infection: results from two international cohort studies. PLoS ONE. 2014;9(7):e101785. doi: 10.1371/journal.pone.0101785. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Wong AT, Tsang OT, Wong MY, et al. Coronavirus infection in an AIDS patient. AIDS. 2004;18:829–830. doi: 10.1097/00002030-200403260-00021. [PubMed] [CrossRef] [Google Scholar]
14. Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020 doi: 10.1002/jmv.25732. [PubMed] [CrossRef] [Google Scholar]
15. EACS and BHIVA statement on risk of COVID-19 for people living with HIV (PLWH). https://www.eacsociety.org/home/covid-19-and-hiv.html
16. Robert-Koch Institute, Berlin, Germany. Corona virus disease 2019. Daily situation report. Accessed 25 Apr 2020. https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-25-en.pdf?__blob=publicationFile
17. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 doi: 10.1001/jama.2020.6775. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama Japan. Euro Surveill. 2020 doi: 10.2807/1560-7917.ES.2020.25.10.2000180. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020 doi: 10.1056/NEJMoa2006100. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Stecher M, Schommers P, Schmidt D, et al. Antiretroviral treatment indications and adherence to the German–Austrian treatment initiation guidelines in the German ClinSurv HIV cohort between 1999 and 2016. Infection. 2019;47:247–255. doi: 10.1007/s15010-018-1248-8. [PubMed] [CrossRef] [Google Scholar]
21. Machnowska P, Meixenberger K, Schmidt D, et al. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter study cohort. PLoS ONE. 2019;14(1):e0209605. doi: 10.1371/journal.pone.0209605. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35:e79. doi: 10.3346/jkms.2020.35.e79. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14:64–68. doi: 10.5582/bst.2020.01030. [PubMed] [CrossRef] [Google Scholar]
24. Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19) J Intern Med. 2020 doi: 10.1111/joim.13063. [PubMed] [CrossRef] [Google Scholar]
25. Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101:42–46. doi: 10.1016/j.jhin.2018.09.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001282. [PubMed] [CrossRef] [Google Scholar]
27. US Department of Health and Human Services. Interim guidance for COVID-19 and persons with HIV. https://aidsinfo.nih.gov/guidelines/html/8/covid-19-and-persons-with-hiv–interim-guidance-/554/interim-guidance-for-covid-19-and-persons-with-hiv.
28. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 doi: 10.1001/jama.2020.6019. [PubMed] [CrossRef] [Google Scholar]
29. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;25:117592. doi: 10.1016/j.lfs.2020.117592. [CrossRef] [Google Scholar]
30. Randomized clinical trial for the prevention of SARS-CoV-2 infection (COVID-19) in healthcare personnel (EPICOS). https://clinicaltrials.gov/ct2/show/NCT04334928?cond=Randomized+clinical+trial+for+the+prevention+of+SARS-CoV-2+infection+%28COVID-19%29+in+healthcare+personnel&draw=2&rank=1
More information: The U.S. Centers for Disease Control and Prevention has more on HIV and COVID-19.
